Abstract:Fang Deng, 1, 2, &ast Jun Ma 3, &ast 1 Department of Psychiatry, Wuhan Mental Health Center, Wuhan, Hubei, People's Republic of China; 2 Wuhan Hospital for Psychotherapy, Wuhan, Hubei, People's Republic of China; 3 Department of Psychiatry, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China &astThese authors contributed equally to this work Correspondence: Jun Ma, Department of Psychiatry, Renmin Hospital of Wuhan University, No. 99 Zhangzhidong Road, Wuhan, Hubei, People's Republic of China, Email Background: Dyslipidemia is frequently comorbid with schizophrenia (SCZ), and both conditions often demonstrate significant gender differences in their clinical features. This study specifically focuses on investigating the prevalence of dyslipidemia and the factors that contribute to it in initial-treatment and drug-naïve (ITDN) SCZ patients, specifically focusing on gender differences. Methods: A total of 224 male ITDN SCZ patients and 424 female ITDN SCZ patients were included in this study. Socio-demographic and general clinical data of the patients were collected, and routine biochemical parameters, such as lipid levels, fasting blood glucose, thyroid function, renal function, and blood cell counts, were measured. Patients were also assessed for psychopathology and disease severity using the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression Scale - Severity of Illness (CGI-SI), respectively. In addition, a lipids score was calculated for assessing the severity of dyslipidemia. Results: The study revealed that the prevalence of dyslipidemia in male patients was 34.02% (83/224), whereas 33.25% (141/424) in females, indicating no statistically significant difference (χ 2 = 0.04, p = 0.841). For males, the risk factors for dyslipidemia were high education levels and diastolic blood pressure (DBP), while red blood cell count (RBC) as a protective factor. Additionally, DBP was identified as a risk factor for dyslipidemia score. In females, systolic blood pressure (SBP) was identified as a risk factor for dyslipidemia, while being married and creatinine (CRE) levels were found to be protective factors. Moreover, SBP was revealed as a risk factor for dyslipidemia score. Conclusion: No significant gender differences were observed in the prevalence of dyslipidemia among the ITDN SCZ patients. However, notable gender differences were identified in the factors influencing dyslipidemia and its severity within this group. These findings suggest the necessity of implementing gender-specific interventions to address the potential risk factors associated with dyslipidemia. Keywords: gender difference, dyslipidemia, lipid levels, schizophrenia, drug-naïve Schizophrenia (SCZ) is a prevalent and chronic mental illness with a multifaceted etiology. 1 Recent research has highlighted a higher susceptibility to secondary endocrine and metabolic disorders among individuals with SCZ. 2 Notably, dyslipidemia, a widely prevalent metabolic disorder, frequently occurs in SCZ patients. 3,4 The presence of dyslipidemia in SCZ patients is significantly associated with elevated morbidity and mortality rates from cardiovascular diseases, as well as reduced life expectancy. 5 Additionally, dyslipidemia has been identified as a significant biological factor associated with cognitive impairment, suicide attempts, and aggressive behavior. 6–8 Hence, comprehensively understanding dyslipidemia in SCZ patients and delineating its clinical characteristics are essential for effective clinical management. There is increasing evidence suggesting that dyslipidemia may be present even before the onset of psychiatric disorders and during the first psychotic episode. 9,10 In individuals at risk for mental illness, including those with subthreshold symptoms, reductions in high-density lipoprotein (HDL) levels have been observed. 11 Moreover, genome-wide association analyses have shown shared genetic loci between SCZ and cardiovascular disease risk factors, such as high-density lipoprotein (HDL) and low-density lipoprotein (LDL). 12,13 These findings indicate that dyslipidemia is inherent in SCZ. Dyslipidemia generally exhibits significant gender differences in both diagnosis and treatment. 14–16 As observed in the general population, men tend to have a higher prevalence of cardiovascular disease compared to premenopausal women. However, after menopause, the prevalence of cardiovascular disease in women gradually increases to match that of men. 17,18 These disparities can be attributed, in large part, -Abstract Truncated-

Sex differences in plasma lipid profiles, but not in glucose metabolism in patients with first-episode antipsychotics-naïve schizophrenia

Sex Difference in Effects of Typical and Atypical Antipsychotics on Glucose-Insulin Homeostasis and Lipid Metabolism in First-Episode Schizophrenia.

Male Sex May Be Associated with Higher Metabolic Risk in First-Episode Schizophrenia Patients: A Preliminary Study

Glucose Metabolism and Sex Hormones in Male Patients with Medication-naïve First-episode Schizophrenia: A Large-scale Cross-sectional Study

Relationship Between Insulin Resistance, Dyslipidaemia and Positive Symptom in Chinese Antipsychotic-Naive First-Episode Patients with Schizophrenia

Abnormal glucose metabolism is associated with clinical symptoms of adolescent-onset patients with first-episode drug-naive schizophrenia

The Comparison of Glycometabolism Parameters and Lipid Profiles Between Drug-Naïve, First-Episode Schizophrenia Patients and Healthy Controls

Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese

Gender Differences in Prevalence and Associated Factors of Metabolic Syndrome in First-Treatment and Drug-Naïve Schizophrenia Patients.

Gender Differences in Prevalence and Associated Factors of Dyslipidemia in Initial-Treatment and Drug-Naïve Schizophrenia Patients

Relationships Between Dorsolateral Prefrontal Cortex Metabolic Change and Cognitive Impairment in First-Episode Neuroleptic-Naive Schizophrenia Patients.

Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia: relationships with clinical phenotypes and cognitive deficits.

Reduced Levels and Disrupted Biosynthesis Pathways of Plasma Free Fatty Acids in First-Episode Antipsychotic-Naïve Schizophrenia Patients

Sex Differences in Pharmacotherapy of Schizophrenia:Findings from National Survey 2012 on Use of Psychotropic Medications

Differing Prevalence and Correlates of Metabolic Syndromes Between Chlorpromazine and Clozapine: A 10-year Retrospective Study of a Male Chinese Cohort

Prevalence and correlates of dyslipidemia in first-episode and drug-naïve major depressive disorder patients with comorbid abnormal glucose metabolism: Sex differences

Cardiometabolic biomarkers and comorbid metabolic syndrome in schizophrenia: A cross-sectional study of long-term clozapine/olanzapine users

Gender Differences in Never-Medicated First-Episode Schizophrenia and Medicated Chronic Schizophrenia Patients.

The Glycometabolism Abnormality among Schizophrenia Patients

- Olanzapine and fecal microbiota transplantation from antipsychotic-naïve schizophrenia patients alter metabolic profiles differentially in male and female mice.

Long-term metabolic side effects of second-generation antipsychotics in Chinese patients with schizophrenia: A within-subject approach with modelling of dosage effects